about
Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trialDrugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitisDrugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitisMetabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential linkNonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and managementTreatment of non-alcoholic fatty liver diseaseThe therapy of insulin resistance in other diseases besides type 2 diabetesFatty liver disease in diabetes mellitusRole of diet on non-alcoholic fatty liver disease: An updated narrative reviewStrategies to rescue steatotic livers before transplantation in clinical and experimental studiesCellular and molecular mechanisms of metformin: an overviewNew promises for metformin: advances in the understanding of its mechanisms of actionMetformin and metabolic diseases: a focus on hepatic aspectsTreatment of metabolic syndromeLow concentrations of metformin selectively inhibit CD133⁺ cell proliferation in pancreatic cancer and have anticancer actionMolecular mediators of hepatic steatosis and liver injuryLocal and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaBSources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.Treatment of nonalcoholic fatty liver disease: role of AMPK.Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology.Metformin use in children with obesity and normal glucose tolerance--effects on cardiovascular markers and intrahepatic fat.Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review.Metformin in nonalcoholic steatohepatitis: a randomized controlled trialObesity as the common soil of non-alcoholic fatty liver disease and diabetes: Role of adipokines.Non-alcoholic fatty liver disease: An expanded reviewMetformin ameliorates hepatic steatosis and improves the induction of autophagy in HFD‑induced obese mice.Betaine improved adipose tissue function in mice fed a high-fat diet: a mechanism for hepatoprotective effect of betaine in nonalcoholic fatty liver disease.Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas.Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma.Is there an effective therapy available for non-alcoholic fatty liver disease?Treatment options for nonalcoholic Fatty liver diseaseManagement of nonalcoholic fatty liver disease: an evidence-based clinical practice review.Exposure to hydrogen peroxide induces oxidation and activation of AMP-activated protein kinase.Palmitoleate induces hepatic steatosis but suppresses liver inflammatory response in mice.Current status of therapy in nonalcoholic Fatty liver disease.Nonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective.Pathogenesis and therapeutic approaches for non-alcoholic fatty liver diseaseQuantitative analysis of hepatic fat fraction by single-breath-holding MR spectroscopy with T₂ correction: phantom and clinical study with histologic assessment.Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium.AMPK as Target for Intervention in Childhood and Adolescent Obesity
P2860
Q22242637-6933E3B2-01F9-41FE-9350-31A0C6CA60BDQ24197984-9686BF83-F8FD-48BF-9BB3-5F587052FEDBQ24246447-1AAC6FB9-1AD1-482D-9DE4-CDBDE7DDB106Q24631619-787C2EC5-E394-4F67-9B4C-A8D770AD4247Q24649618-47BB967D-8D0B-4439-BA4F-C14C9B17E966Q24655572-AE92689A-1D02-4976-8517-A1CF70C5D069Q26822399-488CA6F5-8577-4102-8396-2830E1256DB2Q26996360-757F9257-C6E8-4B8E-9289-14C6D5E4F4D4Q27000333-452D8785-C08C-4749-8BF4-B46CA97C7952Q27003912-77F340AB-396B-4837-A719-7CE40C397B68Q27013561-DBD55E07-2F2F-42B8-B5C3-EE75D141F7F7Q27023545-8AEAAA26-7290-4E06-8F6D-A567191E9CD3Q28082736-4B3E667C-DCB9-4F50-A279-15FB74DE257AQ28168652-CE910EE2-CC95-4F95-A633-86DF30ED683CQ28487772-1AD935D8-08C0-449E-AF91-679C8F40F84FQ29616709-7F2C38C0-5FE2-46E6-AAC9-A4E235FFE9FFQ29619314-4A82B9BD-9843-4E64-878F-15D2E4838FA5Q29619334-FECCE120-828D-4109-A88E-D8900313B3ADQ30248230-6629F11F-C346-4535-A9A8-F5462594B43AQ30389752-4397BB72-88F2-4723-9912-2670B50CB17CQ30413605-8EA0CE3A-47EC-494E-8BC0-B6CE60CB0236Q33268183-6CBAC7EB-94CB-44BF-916E-938EA5871759Q33597395-9CEA0341-17B2-4EAE-8D05-767B3A7241ADQ33628222-74526960-B5E9-44B0-896E-9C53830840B9Q33789868-1E5EDA2D-E2F9-485D-B58D-091B16ADD602Q33828153-FC7C15D7-7E97-49F4-9B71-1754657BAD38Q33840618-563C4340-EF8E-4C2A-BF23-76B3C2C84A09Q33867088-7274DDEF-2AC3-4609-B944-65FC521468D5Q34008552-C022BC37-D345-4F44-A38D-9AF043A62568Q34076451-737FE15C-6AC9-4F20-8A60-0703D896C5AAQ34156317-CF79C6D7-2F44-4231-A2B5-52128BB351D8Q34168532-57DD23F4-3447-4951-99E8-7240E5F2DA02Q34236772-373AECFB-E092-4B42-B204-B34F5AB33323Q34328111-C6B886F1-BD63-4818-81C6-2F1ABD7F5061Q34408961-2A661A5F-5FC3-4344-90DF-FA7C592B1AC4Q34412650-7FAA5AAA-0B56-4ED3-B5A2-AF6288927F8EQ34449857-6BC34460-F55D-4C8E-BCD9-2F44B3B3DB02Q34504586-462CDF89-955E-4E01-A8EE-BAA6625EDB2EQ34505650-6998ECC3-F60F-43A4-9870-114246C8FD5AQ34557477-CF33EE6C-6B4C-4B12-972F-B73A904C1A88
P2860
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Metformin in non-alcoholic steatohepatitis.
@en
Metformin in non-alcoholic steatohepatitis.
@nl
type
label
Metformin in non-alcoholic steatohepatitis.
@en
Metformin in non-alcoholic steatohepatitis.
@nl
prefLabel
Metformin in non-alcoholic steatohepatitis.
@en
Metformin in non-alcoholic steatohepatitis.
@nl
P2093
P1433
P1476
Metformin in non-alcoholic steatohepatitis
@en
P2093
P304
P356
10.1016/S0140-6736(01)06042-1
P407
P577
2001-09-01T00:00:00Z